NodThera has changed its name to Rezera and announced a Phase 3 development program. Read Press Release

Inflammation, Rezolved.

Better tomorrows start with reducing chronic inflammation today.

We have spent over a decade inventing and developing molecules that block the activity of inflammation where it matters – in the blood vessels, in the heart, and in the brain to change the lives of people living with cardiovascular and neurologic diseases. Our sole focus is shutting down the activity of NLRP3, the upstream ‘switch’ that drives chronic inflammation, without impacting the body’s ability to fight infection.

Our Programs

We aim to reduce chronic inflammation at an early stage of disease, when we have the potential to make a positive long-term impact for people with inflammation-driven cardiovascular and neurologic disease.

HP_Our_Programs
HP_Clinical_Trials

Our Clinical Trials

We believe NLRP3 activity is a major driver of disease severity and progression for hundreds of millions of people living with peripheral artery disease (PAD) worldwide. We plan to initiate a registrational Phase 3 clinical trial in the first half of 2027 to study ruvonoflast in people living with PAD.